You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Her2 Gastro Gastric Esophageal Cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced/Metastatic HER2-positive Breast, Gastric, Gastroesophageal Junction Cancer With Disease Progression Following Anti-HER2

Recruiting
  • Advanced/Metastatic HER2-positive Breast, Gastric, Gastroesophageal Junction Cancer With Disease Progression Following Anti-HER2 Standard of Care Treatment
  • Duarte, California
  • +12 more
Jul 6, 2022

Gastric Cancer, Gastro Esophageal Junctional Cancer, Cancer Trial (68Ga-FAPi-46)

Not yet recruiting
  • Gastric Cancer
  • +2 more
  • (no location specified)
Jun 12, 2023

Gastric Cancer Trial in Philadelphia (Neratinib Pill, Fam-Trastuzumab Deruxtecan-Nxki (TDxD))

Suspended
  • Gastric Cancer
  • Neratinib Pill
  • Fam-Trastuzumab Deruxtecan-Nxki (TDxD)
  • Philadelphia, Pennsylvania
    Fox Chase Cancer Center
Jul 6, 2022

Adenocarcinoma Gastric Stage IV With Metastases, Adenocarcinoma - GEJ Trial in Worldwide (Trastuzumab deruxtecan)

Active, not recruiting
Has Results
  • Adenocarcinoma Gastric Stage IV With Metastases
  • Adenocarcinoma - GEJ
  • Trastuzumab deruxtecan
  • Duarte, California
  • +36 more
Jan 24, 2022

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Trial (SHR-A1811, Ramucirumab / Paclitaxel/

Not yet recruiting
  • HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
  • SHR-A1811
  • Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan
  • (no location specified)
Nov 6, 2023

Gastric or Gastro-esophageal Junction (GEJ) or Esophageal Adenocarcinoma (EAC) Trial in Poland, Spain, United States (NT-I7,

Active, not recruiting
  • Gastric or Gastro-esophageal Junction (GEJ) or Esophageal Adenocarcinoma (EAC)
  • Louisville, Kentucky
  • +5 more
Dec 7, 2022

Metastatic Gastric Cancer, Adenocarcinoma of the Gastro-oesophageal Junction Trial in Amsterdam (Docetaxel, Oxaliplatin,

Active, not recruiting
  • Metastatic Gastric Cancer
  • Adenocarcinoma of the Gastro-oesophageal Junction
  • Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab
  • Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab, Trastuzumab
  • Amsterdam, Netherlands
    Netherlands Cancer Institute
Jan 26, 2021

HER2-positive Advanced Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma Trial (Trastuzumab deruxtecan)

Not yet recruiting
  • HER2-positive Advanced Gastric Cancer
  • HER2-positive Gastroesophageal Junction Adenocarcinoma
  • Trastuzumab deruxtecan
  • (no location specified)
Aug 11, 2023

HER2+ Gastric Cancer/Gastroesophageal Junction Adenocarcinoma Trial (SHR-A1811;SHR-1701;capecitabine;oxaliplatin)

Not yet recruiting
  • HER2+ Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
  • (no location specified)
Jan 3, 2023

Esophageal Tumors, Gastric Tumors Malignant, Breast Cancer Trial in Stockholm ([68Ga]Ga-ABY-025 PET, Biopsy and analysis of HER2

Recruiting
  • Esophageal Neoplasms
  • +3 more
  • [68Ga]Ga-ABY-025 PET
  • Biopsy and analysis of HER2 expression
  • Stockholm, Sweden
    Department of Radiation Physics and Nuclear Medicine, Karolinska
Nov 25, 2022

Gastric Cancer, HER2-low-expressing Gastric Cancer Trial in Shanghai (Disitamab Vedotin, Toripalimab)

Recruiting
  • Gastric Cancer
  • HER2-low-expressing Gastric Cancer
  • Shanghai, China
    Shanghai East Hospital
Oct 9, 2023

HER2-positive Gastric Cancer, Immunotherapy Trial in Shanghai (Disitamab Vedotin combined with fruquintinib and Tislelizumab)

Recruiting
  • HER2-positive Gastric Cancer
  • Immunotherapy
  • Disitamab Vedotin combined with fruquintinib and Tislelizumab
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Aug 8, 2023

Gastric Cancer, Esophageal Cancer Trial (FerroTrace® and FerroMag Sentinel Lymph Node Mapping (SLNM) System)

Not yet recruiting
  • Gastric Cancer
  • Esophageal Cancer
  • FerroTrace® and FerroMag Sentinel Lymph Node Mapping (SLNM) System
  • (no location specified)
Jun 2, 2023

Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma Trial

Not yet recruiting
  • Advanced Esophageal Adenocarcinoma
  • +14 more
  • (no location specified)
Jan 3, 2023

Gastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma Trial in Chuo Ku (TRK-950, Ramucirumab,

Not yet recruiting
  • Gastric Adenocarcinoma
  • +2 more
  • TRK-950
  • +2 more
  • Chuo Ku, Japan
    Osaka International Cancer Institute
Sep 14, 2023

Breast Cancer, Metastatic Breast Cancer, HER2-positive Breast Cancer Trial in Amsterdam (89Zr-DFO*-trastuzumab PET scan)

Recruiting
  • Breast Cancer
  • +5 more
  • 89Zr-DFO*-trastuzumab PET scan
  • Amsterdam, Noord-Holland, Netherlands
    AmsterdamUMC
Jul 12, 2023

HER2-positive Locally Advanced Resectable Gastric Cancer Trial (KN026, KN046, XELOX)

Not yet recruiting
  • HER2-positive Locally Advanced Resectable Gastric Cancer
  • (no location specified)
Sep 3, 2023

Stomach Tumor Trial (Trastuzumab deruxtecan, Afatinib)

Not yet recruiting
  • Stomach Neoplasm
  • (no location specified)
Oct 16, 2023

Colorectal Cancer, Liver Cancer, Gastric Cancer Trial in Créteil, Grenoble, Paris (Acupuncture intervention, No acupuncture)

Not yet recruiting
  • Colorectal Cancer
  • +4 more
  • Acupuncture intervention
  • No acupuncture
  • Créteil, France
  • +4 more
May 12, 2023

Advanced Gastric Carcinoma Trial in Dhaka (Trastuzumab, Oxaliplatin, Capecitabine)

Completed
  • Advanced Gastric Carcinoma
  • Dhaka, Bangladesh
    Bangabandhu Sheikh Mujib Medical University
Aug 15, 2023

Breast Cancer, Gastric Cancer, Gastroesophageal-junction Cancer Trial in Australia (IKS014)

Not yet recruiting
  • Breast Cancer
  • +2 more
  • Concord, New South Wales, Australia
  • +4 more
May 30, 2023

Seismofit® asEstimate of VO2 Peak in Hepato-pancreato-biliary,

Recruiting
  • Hepato-Biliary Carcinoma in Situ Nos
  • +4 more
  • Non-Interventional
  • London, United Kingdom
    The Royal Marsden NHS Foundation Trust
Apr 24, 2023

HER2-positive Advanced Gastric Cancer Trial (trastuzumab, bevacizumab with paclitaxel (triple combination))

Not yet recruiting
  • HER2-positive Advanced Gastric Cancer
  • trastuzumab, bevacizumab with paclitaxel (triple combination)
  • (no location specified)
Dec 6, 2022

MSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H/dMMR Gastric Cancer Trial (S095029, Pembrolizumab 200 mg)

Not yet recruiting
  • MSI-H/dMMR Gastroesophageal-junction Cancer
  • MSI-H/dMMR Gastric Cancer
  • (no location specified)
Oct 30, 2023

Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Gastric Cardia Trial in

Active, not recruiting
  • Adenocarcinoma of the Esophagus
  • +5 more
  • Cleveland, Ohio
    Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Ca
Jul 25, 2022